Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Year 2 Clinical > T2DM Therapeutics > Flashcards

T2DM Therapeutics Flashcards

1
Q

Oral anti-hyperglycaemic agents?

A

Biguanides:
• Metformin

Sulphonylureas:
• Glicazide
• Glibenclamide
• Glimeparide

Thiazolidinediones:
• Pioglitazone

GLP-1 receptor agonists:
• Exenatide
• Exendin
• Liraglutide 
• Lixisenatide 
DPP-4 inhibitors (AKA gliptins)
• Vildagliptin
• Sitagliptin
• Saxagliptin
• Linagliptin

SGLT2 inhibitors:
• Dapagliflozin
• Canagliflozin
• Empagliflozin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Brief mechanism of action of metformin?

A

Increases sensitivity to insulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Dosages available for metformin?

A

500, 850 and 1000mg tablets

Most start on 500mg OD/BD and this is increased slowly, however there is little evidence for a dose >1g BD

Liquid formulation has 500mg in 5ml

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Effects of metformin?

A

Hyperglycaemic Mx - reduced HbA1c by 15-20 mmol/L (lowers insulin resistance)

Hypoglycaemia - does not cause these when used as a monotherapy

Weight - overall, it is weight neutral but it can sometimes reduce weight

Prevents micro and macrovascular complications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Additional effects of Metformin

A

Reduced triglycerides and LDL

Effective in PCOS and NAFLD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Metformin in pregnancy?

A

Safe to use in both gestational DM and pregnancy with pre-existing T2DM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Adverse effects of metformin?

A

GI side effects (anorexia, nausea, vomiting, diarrhoea, abdominal pain, taste disturbance)

Interference with vitamin B12 and folic acid absorption (anaemia is rare though)

Lactic acidosis (most likely in existing severe renal, cardiac or liver failure, due to tissue hypoxia)

Liver failure

Rash

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Occurrence of lactic acidosis with metformin use?

A 
Rarely occurs de novo but patients at risk should be cautioned:
• ACUTE heart failure
• Sepsis
• Acute MI
• Respiratory failure
• Hypotension of any cause
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Metformin use when renal toxicity is a concern?

A

Avoid or stop if eGFR <30ml/min or serum creatinine >150μmol/l

Half dose if eGFR 30-45 ml/min

Temporarily withhold if IV contrast being used, e.g: angiography, CT scan

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Metformin use when liver toxicity is a concern?

A

Discontinue if advanced cirrhosis/liver failure

Discontinue if risk of lactic acidosis, e.g: encephalopathy, alcohol excess

May be beneficial in NAFLD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the 1st line agent for T2DM?

A

Metformin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Generations of sulphonylureas?

A

1st generation (rarely used now):
• Chlorpropramide
• Tolbutamide

2nd generation (shorter-acting):
• Glicazide 40mg OD - 160mg BD
• Glipizide 2.5 mg – 15 mg
• Glibenclamide/glyburide 5 mg - 15 mg OD
• Glimepiride 1 mg - 6 mg OD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Brief mechanism of action of sulphonylureas?

A

Insulin secretagogues that binds to SUR receptors and allow closure of the KATP channel

Causes depolarisation of the cell (as K+ accumulates) and this opens Ca+ channel and allows insulin secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Effects of sulphonylureas?

A

Hyperglycaemic Mx:
• Reduces HbA1c by 15-20 mmol/mol by increasing insulin secretion
• Results in more rapid reduction in hyperglycaemia than insulin sensitizers
• Concern re-acceleration of beta cell demise

Prevent microvascular complications but NOT macrovascular complications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Uses of sulphonylureas?

A

Only used 1st line in underweight T2DM or 2nd line, as add on to metformin, or in those intolerant to metformin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Adverse affects of sulphonylureas?

A

Hypoglycaemia (more so in older agents); particular care must be taken in elderly-frail patients and those with alcohol excess and liver disease

Weight gain (only used 1st line in underweight patients)

GI upset and headache

Rarely, hypersensitivity, blood dyscrasias and liver dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

In whom should sulphonylureas be avoided?

A

Severe renal or hepatic failure

18
Q

Brief mechanism of action of Thiazolidinediones (TZDs)?

A

PPARγ agonists; PPARγ is a receptor mostly found in adipose tissue, and also in skeletal muscle and liver, so these drugs target fat cells

Genes activated inc. those than encode:
• Lipoprotein lipase (hydrolysis of lipids found in lipoproteins)
• Fatty acid transport protein and fatty acid CoA synthase (allow lipogenesis and adipocyte differentiation)
• GLUT4 (increases glucose uptake and utilisation)

19
Q

Effects of TZDs?

A

Hyperglycaemia management:
• Reduces HbA1c by 15-20 mmol/mol, by increasing insulin sensitivity

Hypoglycaemia (not if used without an SU)

Weight GAIN due to increase in subcutaneous, not visceral, fat and fluid retention

Heart failure (due to fluid retention)

Prevents MACROvascular complications but not microvascular

20
Q

Complications of Glitazone drugs?

A

Increase risk of hip fractures (not recommended in those >65 years)

21
Q

Which classes of drugs act on the incretin pathways?

A

GLP-1 receptor agonists

DPP-4 inhibitors

These are both insulin secretagogues

22
Q

Describe the incretin effect

A

Amplification of insulin secretion observed when glucose is taken orally as opposed to infused IV, to provide identical plasma glucose conc.

Intestinal secretion of insulin:
• GIP from K cells
• GLP-1 from L cells
These have a very short 1/2-life and are changed into inactive metabolites by DPP-4; they are cleared by the kidneys

23
Q

Administration of Exenatide?

A

Levels increase 4-6 hours after dose

Given twice daily as a subcutaneous injection

24
Q

Administration of Exendin LAR?

A

Administered once weekly

25
Q

Administration of Liraglutide?

A

Most commonly used in this class; it is a GLP-1 analogue that is DPP-4 resistant, so it has a long half-life (10-14 hours)

Given as a once daily injection

26
Q

Administration of Lixisenatide?

A

A GLP-1 analogue

Given once daily

27
Q

Benefits of GLP-1 receptor agonists?

A
  • Promote insulin secretion from pancreas without hypoglycaemia
  • Suppress glucagon (which is increased in T2DM)
  • Decrease gastric emptying to allow early satiety
  • Act on hypothalamus to reduce appetite, resulting weight loss (~3kg)
28
Q

Disadvantages of GLP-1 receptor agonists?

A
  • Nausea (usually resolves in most by 6-8 weeks)
  • Injectable
  • Pancreatitis (due to increased β-cell growth) and potential for pancreatic cancer
29
Q

Benefits of DPP-4 inhibitors?

A

Promote insulin secretion from pancreas without hypoglycaemia

Suppress glucagon (which is increased in T2DM)

Weight neutral

30
Q

Disadvantages of DPP-4 inhibitors?

A

Very limited side effects

Not that potent

No weight loss (but there is no weight gain either)

Pancreatitis and potential risk of pancreatic cancer

31
Q

Brief mechanism of action of SGLT2 inhibitors?

A

Decrease uptake of sugar by ~1/4; this is excreted in the urine

They also REDUCE CV MORTALITY

32
Q

Disadvantages of SGLT2 inhibitors?

A

Sugar in the urine increases thrush incidence and there is a possible increase in urine infections

33
Q

Difference between the use of insulin in T2DM and T1DM?

A

In T2DM:
• Less use of the basal bolus (it may be used)
• More use of basal insulin

34
Q

Use of insulin in T2DM?

A

Usually, once people fail on non-insulin therapies:
• Once daily NPH (isophane) insulin is added to metformin (+/- SU)

If this is ineffective, change to BD NPH insulin OR mixed insulin (Humulin M3)

35
Q

Summarise SUs?

A

Potent
Weight gain
Hypo episodes

36
Q

Summarise TZDs?

A

Potent
Weight gain
Heart failure and fractures

37
Q

Summarise DPP-4 inhibitors?

A

Weight neutral
No hypo episodes
Concern with pancreatitis and pancreatic cancer

38
Q

Summarise SGLT2 inhibitors?

A

Weight loss
No hypos
Thrush/UTIs
CV benefit

39
Q

Summarise GLP-RA (e.g: liraglutide/exenatide/lixisenatide)?

A

Injectable
Weight loss
Concern with pancreatisis and pancreatic cancer

40
Q

Non-drug therapies for T2DM?

A

Weight loss

Bariatric surgery, e.g: gastric banding, recommended for BMI >35; remission rates are higher than with conventional treatment and dietary advice but there are many other problems assoc. with surgery

Year 2 Clinical (119 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions